Rabacfosadine (RAB), a novel double prodrug of the acyclic nucleotide phosphonate PMEG, preferentially targets neoplastic lymphocytes with reduced off target toxicity. Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity. The purpose of this study was to evaluate RAB's safety and efficacy at 2 different doses every 21 days in dogs with relapsed B-cell lymphoma. Dogs that had failed 1 doxorubicin-based chemotherapy protocol were eligible for inclusion in this prospective trial. Once enrolled, dogs were randomized to receive RAB at either 0.82 mg/kg or 1.0 mg/kg as a 30-minute IV infusion every 21 days for up to 5 treatments.
| INTRODUCTION
Multicentric lymphoma is one of the most common cancers in dogs. 1 The "gold standard" treatment generally consists of a multi-agent doxorubicin (DOX)-based chemotherapy regimen (eg, a CHOP-based protocol including cyclophosphamide, doxorubicin, vincristine, and prednisone), and clinical remission is a realistic goal. Approximately 85%-90% of dogs with lymphoma will respond to this treatment; however, few dogs are cured because of the nearly inevitable development of drug-resistant relapse. [1] [2] [3] [4] When resistance to CHOPbased treatment occurs, clinicians must utilize different cytotoxic agents, preferably agents with distinctive mechanisms of action and mechanisms of resistance from drugs in the CHOP-based regimen.
Rabacfosadine (RAB, formerly known as GS-9219 and subsequently VDC-1101) is a nucleotide analog with a unique mechanism of action, making it an attractive treatment option for lymphoma, including CHOP-relapsed or refractory disease. Rabacfosadine, a prodrug of 9-(2-phosphonylmethoxyethyl) guanine (PMEG), has a short half-life in plasma and preferentially targets activated or neoplastic lymphoid cells. Once inside the cell, RAB undergoes enzymatic hydrolysis to form 9-(2-phosphonylmethoxyethyl)-N(6)-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) which is deaminated to yield PMEG.
PMEG is subsequently diphoshphorylated to the active metabolite, PMEGpp. PMEGpp induces cytotoxicity through inhibition of DNA polymerases α, δ and ε, ultimately inhibiting DNA synthesis and/or repair. 5 The intracellular metabolism of RAB to PMEG and ultimately to PMEGpp permits clinical advantages over administration of PMEG itself. When compared with PMEG, it has been demonstrated that RAB more effectively loads peripheral blood mononuclear cells (PMBCs) and lymph nodes with significantly lower distribution in, and toxicity to, the kidneys and gastrointestinal tract. 5 Previous studies evaluating RAB in both treatment naive and relapsed or treatment-refractory dogs with lymphoma have reported overall response rates of~50%-100%. [5] [6] [7] As seen with most other cytotoxic agents, dogs with B-cell lymphoma are more likely to respond with significantly longer response durations. 6 A variety of dosing regimens have been evaluated, with 0.82-1.0 mg/kg every 21 days used most frequently and with a lower likelihood of adverse effects as compared with alternate dosing frequencies, with apparently equivalent efficacy. [6] [7] [8] While the drug has been well tolerated, dose limiting toxicities have included neutropenia, dermatopathy and gastrointestinal signs. The dermatopathy is most often characterized as a pruritic focal otitis externa or focal erythemic skin lesions on the dorsum and in the inguinal areas. [6] [7] [8] [9] With supportive therapy and treatment interruption, the dermatopathy generally resolves.
Another unique but potentially life-threatening idiosyncratic toxicity seen with RAB administration is pulmonary fibrosis, which has been recognized in a small number of treated dogs, necessitating careful monitoring of thoracic radiographs for evidence of pulmonary pathology. 6, 9 The objective of this study was to evaluate the safety and efficacy of RAB at 2different doses in dogs with B-cell lymphoma that had relapsed following one initial DOX-based treatment regimen. To achieve this goal, a prospective multi-institutional trial was initiated with the inclusion of 9 tertiary referral oncology specialty sites across North America. The deliverable findings would serve as future guiding principles for the administration of RAB in the setting of relapsed Bcell lymphoma.
| MATERIALS AND METHODS

| Inclusion/exclusion criteria
This study was conducted across 9 study sites including Hope Veteri- with Sodium Chloride for Injection, USP to achieve a total infusion volume of 2 mL/kg and was administered intravenously (IV) over 30 minutes. Treatments were repeated every 21 days for up to 5 total treatments, per the intended label dose. Dogs were evaluated prior to each treatment as outlined in Table 1 .
| Trial design
Treatment response was based on measurements of peripheral target lesions using the Veterinary Cooperative Oncology Group (VCOG) Response Evaluation Criteria for Peripheral Nodal Lymphoma. 10 Dogs experiencing CR received a total of 5 RAB treatments; thereafter, monthly rechecks were performed until PD was noted. Dogs experiencing PR or SD after 5 treatment cycles were considered off-study upon completion of the fifth treatment cycle and censored from outcome analysis at that point. Dogs experiencing PD were removed from the study and were eligible for other treatment as deemed appropriate by the investigator.
| Adverse event assessment
Hematological adverse events (AEs) were evaluated 7 days after the first treatment. Thereafter, clinical, hematological, and biochemical
AEs were assessed every 21 days based on patient history provided by the owner, physical examination and blood work (Table 1) . 
| Statistical analysis
Continuous data were expressed as median and range, and categorical data as frequencies and percentages. All AEs are summarized in Table 3 . Figure 1 shows the highest a If CBC, serum chemistry, and urinalysis were performed and evaluated within 7 days of day 0, these were not repeated on day 0.
b This visit was only required in dogs experiencing a dose-limiting toxicity following the first treatment. was no statistically significant difference between Treatment Groups (P = .51, P = 1.0 and P = .25, respectively). However, dogs experiencing dose delay or dose reduction had a significantly longer PFI than dogs not experiencing dose delay or dose reduction (203 days vs 63 days, P = .023).
In Treatment Group A, there were 6DLTs including 1 grade 
| DISCUSSION
The results of this study provide evidence that RAB is an effective treatment for dogs with B-cell lymphoma that have relapsed following an initial DOX-based chemotherapy regimen. The overall response rate was 74% with a median PFI in responders of 6 months. There were no significant differences between the 2dosages with respect to response rate, PFI, response duration, or
AEs; however, it should be noted that enrolment in Treatment Group
A was discontinued early to allow treatment of more dogs at the intended label dose of 1.0 mg/kg, resulting in limited power to detect Abbreviations: AST, aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatinine phosphokinase; GGT, gamma-glutamyl transferase; SAP, serum alanine transferase. The unique dermatologic toxicity reported previously with RAB 6-9 was noted in both treatment groups in this study. Although in most cases, this AE was mild and self-limiting, it did result in patient withdrawal from the study in 6 dogs. Interestingly, all 6 dogs had responded to RAB at the time of withdrawal, including 4 CR and 2 PR, and it was difficult to ascertain the rationale for premature withdrawal in retrospect. It is not clear why this dermatopathy occurs; however, it has been proposed that it is secondary to drug distribution to the skin. 6 This hypothesis prompted a phase II study evaluating the effect of RAB in the treatment of canine cutaneous T cell lymphoma (CTCL), which reported an ORR of 45%, including 1 CR and 4 PR. 8 Interestingly, a previous study reported that dermatologic toxicity occurred in 37% of dogs treated with RAB and was seen most commonly in the dogs receiving daily or weekly treatments. No skin-related AEs were seen in the every 21-day cohort of dogs. 6 With that being said, all dogs in the CTCL study were treated at a 21-day interval, yet 25% developed drug-related dermatopathies, with 1 dog exiting the study as a result of the AE. 8 The awareness that dermatopathies are possible even with less frequent dosing (ie, every 21 days) is important and should prompt clinicians to closely monitor dogs' skin and ears regardless of RAB dose intensity. With that being said, users are encouraged to manage low-grade dermatopathies with drug holidays and supportive medications, rather than complete discontinuation of RAB.
Pulmonary fibrosis has also been reported previously in dogs receiving RAB. 6, 9 In the previously published lymphoma study, 6 the dogs with pulmonary fibrosis had completed RAB treatment and were subsequently treated with other cytotoxic drugs. Only one of these dogs underwent a necropsy examination where pulmonary fibrosis was confirmed. Of the remaining dogs that underwent necropsy examination, pulmonary changes, characterized by hyperplasia, were seen in only one. While the authors were unable to explain the relationship between RAB administration and the pulmonary pathology, it was concluded that these findings warranted close observation of thoracic imaging in dogs receiving this treatment. 6 Pulmonary fibrosis was also noted in a subsequent study of RAB in dogs with multiple myeloma. 9 In the current study, 1 dog was documented to have grade 5 pulmonary fibrosis, which was first noted 84 days after treatment initiation. However, on necropsy examination, the fibrosis was reported as mild, and lymphoma was found in the lungs, making attribution of the observed dyspnoea challenging. Thoracic radiographic findings are variable in dogs with pulmonary lymphoma, 26 and in some cases, such radiographic abnormalities may easily be mistaken for pulmonary fibrosis. Questions as to the most appropriate use of thoracic radiograph monitoring, as well as the potential benefit of concomitant low-dose corticosteroids are beyond the scope of this study but warrant further investigation. Although pulmonary fibrosis can be lifethreatening, this unique toxicity appears to be relatively infrequent.
Another notable AE was proteinuria, which was seen in 22% of the study population. However, it is unknown if this was related to RAB administration versus the underlying lymphoma or an unrelated cause (eg, lower urinary tract infection). All incidences of proteinuria were mild, and while we do not strongly suspect they were related to RAB administration, further investigation and careful monitoring of RAB-treated dogs are warranted.
One limitation of the study design was that owners were not asked to keep daily dairies at home to prospectively record any potential AEs on a daily basis. 
